The Other Side of Possible…

What does OSOP mean to us?

Agios Supports
Rare Disease Day

What Drives Us?

The many friends and family of Agios employees affected by cancer are what motivates, inspires and drives us.

Melissa McLaughlin
SVP Human Resources

Learn About
Our Research Platform

Our Research Focus

Cancer Metabolism

Inhibit key enzymes in cancer cell specific metabolic pathways to disrupt tumor cell proliferation and survival

Rare Genetic Diseases

Restore defective metabolic pathways in disease cells that cause rare genetic disorders of metabolism

Metabolic
Immuno-Oncology

Alter the metabolic state of immune cells to enhance the body’s anti-tumor response

Boldly Pursuing Excellence and Innovation

We are a research-driven organization focused on creating transformative medicines by combining expertise in metabolism and precision medicine.

research platform

The Spirit of Agios

The Spirit of Agios

At Agios, our culture and values are embodied in the Greek word Arete, the ancient ideal of excellence and fulfillment of one’s potential to which our employees aspire. Together, we are driven by a boundless passion for our work, and we pride ourselves on fostering an interconnected environment that encourages creative scientific collaboration across disciplines.

explore agios’ culture explore agios’ values

Passion for Discovery

our pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.


CANDIDATE

Drug Discovery
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

APPROVED
R/R AML
 
Phase 1 Dose-Escalation and Expansion Ongoing
 
EU
U.S.
Frontline AML Monotherapy
Phase 1 Dose-Escalation and Expansion
U.S.
IC Eligible Frontline AML
 
Phase 1b 7+3 Combo
IC Ineligible Frontline AML
 
Phase 1/2 Azacitidine Combo
Phase 3 AGILE Azacitidine Combo
Cholangio
 
 Phase 1 Dose-Escalation and Expansion
Phase 3 ClarlDHy
Glioma
 
Perioperative Study
Solid Tumors
Phase 1 Dose-Escalation and Expansion
R/R AML
 
Phase 3 IDHENTIFY
 EU
U.S.
IC Eligible Frontline AML
 
Phase 1b 7+3 Combo
IC Ineligible Frontline AML
 
Phase 1/2 Azacitidine Combo
  • Celgene has worldwide development and commercialization rights.Agios has U.S. co–promotion and royalty rights.
Transfusion Independent PK Deficiency
 
Phase 2 DRIVE PK
Phase 3 ACTIVATE
Transfusion Dependent PK Deficiency
Phase 3 ACTIVATE-T
Thalassemia
Phase 2 Study
Glioma
 
Perioperative Study
Solid Tumors
Phase 1 Dose-Escalation and Expansion
MTAP-Deleted Tumors
 
Phase 1 Dose-Escalation and Expansion
  • Subject to Celgene Option Joint Worldwide Collaboration.

IC = Intensive Chemotherapy

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Recent News & Events

02/14/2019

Agios Reports Fourth Quarter and Full Year 2018 Financial Results
read more

01/31/2019

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019
read more

01/07/2019

Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value
read more

12/28/2018

Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019
read more
Agios Home

Agios has a dynamic culture that supports our employees’ unwavering commitment to science and patients.

career opportunities